Literature DB >> 33321690

Dysgerminoma with a Somatic Exon 17 KIT Mutation and SHH Pathway Activation in a Girl with Turner Syndrome.

Ada Gawrychowska1, Ewa Iżycka-Świeszewska2, Beata S Lipska-Ziętkiewicz3,4, Dominika Kuleszo5, Joanna Bautembach-Minkowska6, Marcin Łosin7, Joanna Stefanowicz1,8,9.   

Abstract

This article reports a case of a 7-year-old girl with Turner syndrome, treated with growth hormone (GH), who developed ovarian dysgerminoma. The patient karyotype was mosaic for chromosome Xq deletion: 46,X,del(X)(q22)/45,X. No Y chromosome sequences were present. Molecular studies revealed the presence of a driving mutation in exon 17 of the KIT gene in the neoplastic tissue, as well as Sonic-hedgehog (SHH) pathway activation at the protein level. The patient responded well to chemotherapy and remained in complete remission. This is the first case of dysgerminoma in a Turner syndrome patient with such oncogenic pathway.

Entities:  

Keywords:  HH signaling; Turner syndrome; dysgerminoma; growth hormone treatment; somatic exon 17 KIT mutation

Year:  2020        PMID: 33321690      PMCID: PMC7763800          DOI: 10.3390/diagnostics10121067

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  28 in total

Review 1.  Recombinant growth hormone for children and adolescents with Turner syndrome.

Authors:  L Baxter; J Bryant; C B Cave; R Milne
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Possible alternative strategy for stage I imatinib-sensitive testicular seminoma; lessons from a case associated with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  A Okamura; K Wakahashi; S Ishii; Y Katayama; K Yamamoto; T Matsui
Journal:  Ann Oncol       Date:  2010-01-15       Impact factor: 32.976

3.  Cytogenetic and molecular investigations of Y chromosome sequences and their role in Turner syndrome.

Authors:  C R Quilter; K Taylor; G S Conway; N Nathwani; J D Delhanty
Journal:  Ann Hum Genet       Date:  1998-03       Impact factor: 1.670

4.  The genetic landscape of 87 ovarian germ cell tumors.

Authors:  Els Van Nieuwenhuysen; Pieter Busschaert; Patrick Neven; Sileny N Han; Philippe Moerman; Michalis Liontos; Maria Papaspirou; Jolanta Kupryjanczyk; Claus Hogdall; Estrid Hogdall; Ana Oaknin; Angel Garcia; Sven Mahner; Fabian Trillsch; David Cibula; Florian Heitz; Nicole Concin; Paul Speiser; Helga Salvesen; Jalid Sehouli; Diether Lambrechts; Ignace Vergote
Journal:  Gynecol Oncol       Date:  2018-08-28       Impact factor: 5.482

Review 5.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

Authors:  Marilyn M Li; Michael Datto; Eric J Duncavage; Shashikant Kulkarni; Neal I Lindeman; Somak Roy; Apostolia M Tsimberidou; Cindy L Vnencak-Jones; Daynna J Wolff; Anas Younes; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2017-01       Impact factor: 5.568

6.  Cancer incidence in women with Turner syndrome in Great Britain: a national cohort study.

Authors:  Minouk J Schoemaker; Anthony J Swerdlow; Craig D Higgins; Alan F Wright; Patricia A Jacobs
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

7.  A Rare Case of Embryonal Carcinoma in a Patient with Turner Syndrome without Y Chromosomal Material but Mutations in KIT, AKT1, and ZNF358 Demonstrated Using Exome Sequencing.

Authors:  Claus H Gravholt; Ole L Dollerup; Lone Duval; Else Mejlgaard; Katrine Stribolt; Søren Vang; Britt E Laursen; Michael Knudsen; Kasper Thorsen; Remko Hersmus; Leendert H J Looijenga; Kirstine Stochholm
Journal:  Sex Dev       Date:  2017-12-02       Impact factor: 1.824

8.  Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers.

Authors:  Christina E Hoei-Hansen; Sigrid M Kraggerud; Vera M Abeler; Janne Kaern; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2007-02-02       Impact factor: 27.401

9.  Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study.

Authors:  Anthony J Swerdlow; Rosie Cooke; Dominique Beckers; Birgit Borgström; Gary Butler; Jean-Claude Carel; Stefano Cianfarani; Peter Clayton; Joël Coste; Annalisa Deodati; Emmanuel Ecosse; Ruth Gausche; Claudio Giacomozzi; Anita C S Hokken-Koelega; Aysha J Khan; Wieland Kiess; Claudia E Kuehni; Primus-E Mullis; Roland Pfaffle; Lars Sävendahl; Grit Sommer; Muriel Thomas; Anders Tidblad; Sally Tollerfield; Liesbet Van Eycken; Gladys R J Zandwijken
Journal:  J Clin Endocrinol Metab       Date:  2017-05-01       Impact factor: 5.958

10.  State of the art review in gonadal dysgenesis: challenges in diagnosis and management.

Authors:  Bonnie McCann-Crosby; Roshanak Mansouri; Jennifer E Dietrich; Laurence B McCullough; V Reid Sutton; Elise G Austin; Bruce Schlomer; David R Roth; Lefkothea Karaviti; Sheila Gunn; M John Hicks; Charles G Macias
Journal:  Int J Pediatr Endocrinol       Date:  2014-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.